|Home | English version | Mappa | Commenti | Sondaggio | Staff | Contattaci||Cerca nel sito|
|Istituto di scienza dell'alimentazione|
Contributo in rivista
Tipo: Articolo in rivista
Titolo: Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function.
Anno di pubblicazione: 2001
Formato: Elettronico Cartaceo
Autori: Ishioka GY, Fikes J, Qin M, Gianfrani C, Chesnut RW, Kahn LE, Streeter PR, Woulfe SL, Sette A.
Affiliazioni autori: Epimmune Inc., 5820 Nancy Ridge Dr., San Diego, CA 92121, USA Pharmacia Corporation, 700 Chesterfield Village Parkway, St Louis, MO 63198, USA Istituto di Scienza dell'Alimentazione CNR
Abstract: Recently, a dual receptor agonist for human Flt3 and G-CSF receptors, progenipoietin-4 (ProGP-4), was shown to be highly effective in expanding DC in vivo. In this study, we examined the immunological activity of ProGP-4-generated dendritic cell (DC) in an HLA-A2.1 transgenic mouse system. ProGP-4 DC were found to be approximately equivalent in presenting a cytotoxic T lymphocyte (CTL) peptide to a CTL line in vitro compared with bone marrow (BM)-derived DC and >20-fold more efficient than macrophages or B cells, and >100-fold better than BM-DC, macrophages, or B cells at presenting PADRE, a universal helper T cell epitope, to a T cell clone. The heightened epitope presentation by ProGP-4 DC was paralleled in vivo inasmuch as a >6-fold increase in CTL induction was observed compared with other APC populations following ex vivo loading with peptide. The in vitro and in vivo CTL responses stimulated by ProGP-4 DC could be further augmented by either culturing with tumor necrosis factor-alpha (TNF-alpha) or co-loading with PADRE. Collectively, our results indicate that peptide-loaded ProGP-4-generated DC demonstrate potent antigenicity and immunogenicity for CTL, making them an attractive component of epitope-based vaccines.
Pagine da: 3710
Pagine a: 3719
Numero volume: 19
Referee: Sė: Internazionale
|Home | Il CNR | I servizi | News | Eventi | Istituti | Focus|